Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

PHASE3CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Moderate or Severe Submental Fullness
Interventions
DRUG

Deoxycholic acid injection

DRUG

Placebo

Phosphate buffered saline placebo for injection

Trial Locations (29)

2440

Investigational Site, Geel

3600

Investigational Site, Genk

10827

Investigational Site, Berlin

13705

Investigational Site, Berlin

15831

Investigational Site, Mahlow

20146

Investigational Site, Hamburg

20354

Investigational Site, Hamburg

23538

Investigational Site, Lübeck

25030

Investigational Site, Besançon

28043

Investigational Site, Madrid

34121

Investigational Site, Kassel

41236

Investigational Site, Mönchengladbach

44791

Investigational Site, Bochum

45657

Investigational Site, Recklinghausen

48159

Investigational Site, Münster

75007

Investigational Site, Paris

75116

Investigational Site, Paris

76100

Investigational Site, Rouen

79104

Investigational Site, Freiburg im Breisgau

91054

Investigational Site, Erlangen

93042

Investigational Site, Regensburg

06000

Investigational Site, Nice

01067

Investigational Site, Dresden

01097

Investigational Site, Dresden

00185

Investigational Site, Roma

B74 2UG

Investigational Site, Birmingham

CF10 2GF

Investigational Site, Cardiff

W1G 8SF

Investigational Site, London

LE11 1TZ

Investigational Site, Loughborough

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Kythera Biopharmaceuticals

INDUSTRY